Samsara is the IBD Stock of the Day ahead of its Q4 earnings report due March 6. Samara stock has forged a cup base, rebounding from a sell-off.

Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due ...

In terms of fundamentals, Omnicell has posted three quarters of increasing earnings growth. Revenue growth has also moved ...

Brady Cl A saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 72. Please watch the ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

A study led by the University of Birmingham found that vancomycin, a commonly used antibiotic for diarrhea, could effectively ...

The inflammatory bowel disease (IBD), develops due to an incurable autoimmune liver disease called primary sclerosing ...

A recent major OECD report has warned of a looming crisis in the European health workforce. In the third in our series on the ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...

While the rising incidence is due in part to environmental factors including ultra-processed foods and smoking, the ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

Queensland has the third highest prevalence of a debilitating bowel disease that impacts 180,000 Australians, costing ...